World Conference on Lung Cancer

Lyudmila A. Bazhenova, MD, explains the impact of having larotrectinib results in a lung cancer cohort, as seen in a presentation of data from 14 patients, given during the 2020 World Conference on Lung Cancer Singapore.

Antitumor activity was demonstrated with trastuzumab deruxtecan treatment in patients with HER2-overexpressing non–small cell lung cancer, regardless of HER2 expression levels, according to interim findings from a cohort of the phase 2 DESTINY Lung-01 trial.

Progression-free survival and overall survival benefits, combined with a higher objective response rate, confirmed the noninferiority of nab-paclitaxel compared with docetaxel in previously treated patients with advanced non–small cell lung cancer, according to phase 3 trial results.

Antitumor activity was seen in the combination of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer, regardless of PD-L1 status or tumor histology.

Treatment with amivantamab induced deep and durable responses as well as promising survival as treatment of patients with previously treated non–small cell lung cancer harboring EGFR exon 20 insertion mutation in phase 1 CHRYSALIS trial.

Patients with checkpoint inhibitor-naïve and refractory composite AXL-positive non—small cell lung cancer, responded to treatmen with the first-in-class oral kinase inhibitor bemcentinib in combination with pembrolizumab, and the compound was well-tolerated, according to updated results from the phase 2 BGBC008 clinical trial.

Sotorasib demonstrated significant benefit in patients with KRAS G12C–mutated advanced non–small cell lung cancer, according to results from the phase 2 portion of the CodeBreaK 100 trial to be presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer.

In the phase 1 RESILIENT trial, patients with small cell lung cancer who failed platinum-based treatment in the first-line setting, displayed encouraging anti-tumor activity and safety, results presented during the 2020 World Conference on Lung Cancer show.

Patients with EGFR-mutant, MET-amplified or -overexpressed non–small cell lung cancer and MET resistance treated with osimertinib in combination with savolitinib may be able to overcome resistance, according to final analysis findings.

In patients with relapsed/refractory small cell lung cancer who did not receive previous checkpoint inhibitor therapy, the addition of the anti–fucosyl-GM1 monoclonal antibody, BMS-986012 to nivolumab demonstrated promising results in a phase 1/2 study.

A correlation between the emergence of immune-related adverse events and presence of mutations was identified in patients with non-small lung cancer receiving immunotherapy.

Long-term follow-up results from KEYNOTE-042 show that pembrolizumab continues to improve survival and response outcomes in patients with PD-L1+ locally advanced or metastatic non–small cell lung cancer.

Overall survival is significantly improved when pembrolizumab is added to platinum-based chemotherapy in the frontline treatment of patients with metastatic nonsquamous non-small cell lung cancer.

Five years of follow-up in KEYNOTE-010 reveals that pembrolizumab can maintain improvement in survival over docetaxel in a non–small cell lung subgroup.

In pretreated patients with advanced small cell lung cancer, treatment with the combination of apatinib and single-agent chemotherapy showed promising efficacy and was well-tolerated, data from a prospective phase 2 study.

When cetuximab (Erbitux) was added to chemotherapy, the risk of death was reduced by 44% for patients with advanced squamous non-small cell lung cancer (NSCLC) whose tumors test positive for EGFR gene amplification.

Osimertinib (AZD9291), the third-generation TKI, demonstrated a 71% objective response rate (ORR) in those with EGFR T790M-mutant non-small cell lung cancer (NSCLC), following resistance to frontline anti-EGFR therapy.

When bevacizumab (Avastin) was added to adjuvant chemotherapy, overall survival (OS) did not improve in patients with surgically resected early-stage non-small cell lung cancer (NSCLC)

Continued treatment with gefitinib (Iressa) beyond progression showed a trend toward better outcomes for those with T790M-negative non-small cell lung cancer (NSCLC).

For patients who have metastatic squamous non-small cell lung cancer (NSCLC) whose tumors were positive for EGFR copy number, as determined by the FISH analysis, survival tended to be better with the addition of necitumumab to their conventional chemotherapy.

Coexisting driver mutations within EGFR-mutant non-small cell lung cancer (NSCLC) could possibly contribute to primary resistance to EGFR-targeted therapy.

Nivolumab (Opdivo) and ipilimumab (Yervoy), a chemotherapy-free regimen, showed activity as a first-line therapy for patients who have advanced non-small cell lung cancer (NSCLC).

Daniel S. Oh, MD, assistant professor of surgery, University of Southern California, Keck School of Medicine, discusses myPlan genetic testing in patients with lung cancer.

By adding bevacizumab (Avastin) to a standard chemotherapy doublet, the risk of death is reduced by 24%, with the risk of disease reducing by 39%, in patients who have malignant pleural mesothelioma (MPM).

The majority of patients under the age of 40 who have lung cancer had tumors with mutations that can be targeted with existing therapies.